STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction
STAG2 mutations predict better survival after transplant in AML, helping doctors identify which patients benefit most from this intensive treatment approach.
This retrospective cohort study found STAG2 mutation is associated with superior posttransplant survival in AML patients receiving low-intensity induction therapy. The finding adds STAG2 status as a clinically relevant prognostic biomarker for transplant outcomes, refining patient selection and post-transplant surveillance strategies.
What the study was
- Study design
- Retrospective cohort study
- Population
- AML/MDS patients receiving low-intensity induction and allogenic transplant
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Blood cancer journal
Why it surfaced
Retrospective cohort study identifying STAG2 mutation as a prognostic biomarker for posttransplant survival in AML; directly applicable to transplant decision-making.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.